Literature DB >> 9311839

Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

J N Flynn1, C A Cannon, J C Neil, O Jarrett.   

Abstract

Cats were immunized with a 46-residue multiepitopic synthetic peptide of feline immunodeficiency virus (FIV) comprising immunodominant epitopes present in the third variable domain of the envelope glycoprotein, transmembrane glycoprotein (TM), and p24 Gag core protein, using Quil A as an adjuvant. All vaccinated cats developed a humoral response which recognized the synthetic peptide immunogen and the intact viral core and envelope proteins. A FIV Gag- and Env-specific effector cytotoxic T-lymphocyte response was also detected in the peripheral blood of vaccinated cats, which peaked at week 30. This response appeared to be major histocompatibility complex restricted. Epitope mapping studies revealed that both the cellular and humoral immune responses were directed principally to a peptide within the TM glycoprotein, CNQNQFFCK. However, vaccination did not confer protection when cats were challenged with the Petaluma isolate of FIV at week 35.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311839      PMCID: PMC192106          DOI: 10.1128/JVI.71.10.7586-7592.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines.

Authors:  M J Hosie; R Osborne; J K Yamamoto; J C Neil; O Jarrett
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

2.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Serological diagnosis of feline immunodeficiency virus infection based on synthetic peptides from Env glycoproteins.

Authors:  A Avrameas; A D Strosberg; A Moraillon; P Sonigo; G Pancino
Journal:  Res Virol       Date:  1993 May-Jun

4.  Enhancement after feline immunodeficiency virus vaccination.

Authors:  M J Hosie; R Osborne; G Reid; J C Neil; O Jarrett
Journal:  Vet Immunol Immunopathol       Date:  1992-12       Impact factor: 2.046

5.  Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.

Authors:  S Lombardi; C Garzelli; C La Rosa; L Zaccaro; S Specter; G Malvaldi; F Tozzini; F Esposito; M Bendinelli
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

6.  Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide.

Authors:  J N Flynn; C A Cannon; J A Beatty; M Mackett; M A Rigby; J C Neil; C Jarrett
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain.

Authors:  A de Ronde; J G Stam; P Boers; H Langedijk; R Meloen; W Hesselink; L C Keldermans; A van Vliet; E J Verschoor; M C Horzinek
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

8.  Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.

Authors:  J K Yamamoto; T Hohdatsu; R A Olmsted; R Pu; H Louie; H A Zochlinski; V Acevedo; H M Johnson; G A Soulds; M B Gardner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

9.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Authors:  M K Gorny; A J Conley; S Karwowska; A Buchbinder; J Y Xu; E A Emini; S Koenig; S Zolla-Pazner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.

Authors:  K H Siebelink; E Tijhaar; R C Huisman; W Huisman; A de Ronde; I H Darby; M J Francis; G F Rimmelzwaan; A D Osterhaus
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  5 in total

1.  Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.

Authors:  Shannon R Roff; Missa P Sanou; Mobeen H Rathore; Jay A Levy; Janet K Yamamoto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Authors:  L Hanlon; D Argyle; D Bain; L Nicolson; S Dunham; M C Golder; M McDonald; C McGillivray; O Jarrett; J C Neil; D E Onions
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 4.  Important mammalian veterinary viral immunodiseases and their control.

Authors:  J R Patel; J G M Heldens; T Bakonyi; M Rusvai
Journal:  Vaccine       Date:  2012-01-17       Impact factor: 3.641

Review 5.  Review of companion animal viral diseases and immunoprophylaxis.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2008-11-27       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.